Company profile: Breath Therapeutics
1.1 - Company Overview
Company description
- Provider of inhaled investigational therapies for rare respiratory diseases, combining novel formulations of existing drugs with cutting-edge inhalation technology. Pipeline includes Liposomal Cyclosporine A for Inhalation for bronchiolitis obliterans syndrome to deliver drug to lungs while minimizing systemic exposure, and inhaled colistimethate sodium for non-cystic fibrosis bronchiectasis targeting Pseudomonas aeruginosa.
Products and services
- Colistimethate Sodium: An investigational inhaled antibiotic for Non-Cystic Fibrosis Bronchiectasis, targeting Pseudomonas aeruginosa infections to reduce pulmonary exacerbations
- Inhaled Drug Delivery Technology: A cutting-edge technology combining novel formulations of existing drugs with inhaled delivery to treat rare respiratory diseases with high unmet medical need
- Liposomal Cyclosporine A for Inhalation (L-CsA-i): An investigational inhaled therapy for Bronchiolitis Obliterans Syndrome, aiming to deliver the drug directly to the lungs while minimizing systemic exposure
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Breath Therapeutics
G-CON
HQ: United States
Website
- Description: Provider of off-site, prefabricated cleanroom units (PODs) for pharmaceutical development and manufacturing, including design, construction, installation and qualification, enabling faster deployment versus traditional cleanroom infrastructure to address rapidly changing requirements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full G-CON company profile →
BAC
HQ: United States
Website
- Description: Provider of affinity purification products and services for the biopharmaceutical market, with CaptureSelect products used from drug discovery to manufacturing of biopharmaceuticals, based on a proprietary platform integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BAC company profile →
Carterra
HQ: United States
Website
- Description: Provider of biotechnology solutions for micro-array deposition technologies, delivering instruments and services that enable multiplexing on planar array surfaces. Offerings include LSA and LSAXT for monoclonal antibody characterization (kinetics, epitope binning), Continuous Flow Microspotter (CFM), sensor chips, kinetics and epitope software, and AI/ML in silico tools for drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carterra company profile →
Evitria
HQ: Switzerland
Website
- Description: Provider of global antibody expression services specialized in CHO-based transient production of recombinant antibodies, including chimeric, bispecific, Fc-optimized, fusion, afucosylated (GlymaxX) and Fc-silenced (STR) variants. Offers bispecific formats (Duobody, IgG-scFvs, Knobs-into-Holes) and transient expression of secreted proteins (scFvs, extracellular domains, cytokines, viral proteins).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evitria company profile →
HiFiBiO Therapeutics
HQ: France
Website
- Description: Provider of proprietary single-cell technologies for drug and biomarker discovery and development, and biotherapeutic antibody candidates that mobilize the immune system, including targets TNFR2, OX-40, BTLA, Gal-9, CCR8, and CXCR5 for solid tumors, myeloid malignancies, B cell lymphomas, and autoimmune diseases; collaborates through open-innovation partnerships with industry and academia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HiFiBiO Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Breath Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Breath Therapeutics
2.2 - Growth funds investing in similar companies to Breath Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Breath Therapeutics
4.2 - Public trading comparable groups for Breath Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →